XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Selected financial info by reportable segment
Selected financial information by reportable segment is presented below (in thousands):
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2018
 
2017
 
2018
 
2017
Revenues, net:
 
 
 
 
 
 
 
Prescription Pharmaceuticals
$
172,163

 
$
182,645

 
$
336,464

 
$
420,024

Consumer Health
18,781

 
16,495

 
38,543

 
32,536

Total revenues, net
190,944

 
199,140

 
375,007

 
452,560

 
 
 
 
 
 
 
 
Gross Profit:
 

 
 

 
 

 
 

Prescription Pharmaceuticals
73,286

 
95,906

 
146,794

 
236,862

Consumer Health
7,993

 
6,863

 
16,713

 
14,676

Total gross profit
81,279

 
102,769

 
163,507

 
251,538

 
 
 
 
 
 
 
 
Operating expenses
172,845

 
88,495

 
280,488

 
162,851

 
 
 
 
 
 
 
 
Operating (loss) income
(91,566
)
 
14,274

 
(116,981
)
 
88,687

Other expenses, net
(12,690
)
 
(7,524
)
 
(23,302
)
 
(16,611
)
 
 
 
 
 
 
 
 
(Loss) Income before income taxes
$
(104,256
)
 
$
6,750

 
$
(140,283
)
 
$
72,076

Revenue from External Customers by Geographic Areas
The following table sets forth the Company’s net revenues by geographic region for the three and six month periods ended June 30, 2018 and 2017. The Domestic region represents sales within the United States of America and its territories while the Foreign region represents sales within all other countries and territories (dollar amounts in thousands):
 
 
Three Months Ended
June 30, 2018
 
Three Months Ended
June 30, 2017
 
Six Months Ended
June 30, 2018
 
Six Months Ended
June 30, 2017
Region
Amount
 
% of Total Revenues
 
Amount
 
% of Total Revenues
 
Amount
 
% of Total Revenues
 
Amount
 
% of Total Revenues
Domestic
$
186,726

 
97.8%
 
$
193,314

 
97.1%
 
$
367,740

 
98.1%
 
$
439,018

 
97.0%
Foreign
4,218

 
2.2%
 
5,826

 
2.9%
 
7,267

 
1.9%
 
13,542

 
3.0%
Total Revenues
$
190,944

 
100.0%
 
$
199,140

 
100.0%
 
$
375,007

 
100.0%
 
$
452,560

 
100.0%